Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00960
|
|||||
| Drug Name |
Zanamivir
|
|||||
| Synonyms |
GANA; (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 139110-80-8; 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid; 4-Guanidino-Neu5Ac2en; 4-Guanidino-NeueAc2en; 4-guanidino-Neu5Ac2en; 5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid; 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid; AK163166; BAC-zanamivir; C12H20N4O7; CHEBI:50663; CHEMBL222813; DSSTox_CID_3749; DSSTox_GSID_23749; DSSTox_RID_77184; GANA; GANA (inhibitor); GG 167; GG-167; GG167; GNA; GR 121167X; GR-121167X; GR121167X; HSDB 7437; L6O3XI777I; MODIFIED SIALIC ACID; Relenza; Relenza (TN); UNII-L6O3XI777I; ZMR; ZNV; Zanamavir; Zanamivir (Relenza); Zanamivir (USAN/INN); Zanamivir [USAN:INN:BAN]; Zanamivir hydrate; zanamivir
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Therapeutic Class |
Antiviral Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C12H20N4O7
|
|||||
| Canonical SMILES |
CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N
|
|||||
| InChI |
InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1
|
|||||
| InChIKey |
ARAIBEBZBOPLMB-UFGQHTETSA-N
|
|||||
| CAS Number |
CAS 139110-80-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 332.31 | Topological Polar Surface Area | 201 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 7 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
-3.2
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:50663
|
|||||
| TTD Drug ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.